Market closed

Akebia Therapeutics/$AKBA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Akebia Therapeutics

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Ticker

$AKBA
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

167
Website
www.akebia.com

AKBA Metrics

BasicAdvanced
$408M
-
-$0.23
0.70
-

$408M

0.7

$2.48

$0.80

2.1M

1.524

1.007

-189.82

-204.748

-2.61%

-9.37%

102.40%

2.243

-7.85

-3.34

-9.888

-12.53%

-28.49%

-6.92%

-50.52%

What the Analysts think about AKBA

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Akebia Therapeutics stock.

AKBA Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AKBA Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

AKBA News

AllArticlesVideos
Q3 2024 Earnings: Hold Akebia Therapeutics

Q3 2024 Earnings: Hold Akebia Therapeutics

Seeking Alpha·2 months ago
Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AKBA

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Akebia Therapeutics stock?

Akebia Therapeutics (AKBA) has a market cap of $408M as of January 15, 2025.

What is the P/E ratio for Akebia Therapeutics stock?

The price to earnings (P/E) ratio for Akebia Therapeutics (AKBA) stock is 0 as of January 15, 2025.

Does Akebia Therapeutics stock pay dividends?

No, Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Akebia Therapeutics dividend payment date?

Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders.

What is the beta indicator for Akebia Therapeutics?

Akebia Therapeutics (AKBA) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.